Novo Nordisk reports positive results from first phase 3 trial with long-acting factor IX for treatment of haemophilia B
2013-05-17 · Novo Nordisk A/S · original novonordisk.com ↗
Bagsværd, Denmark, 17 May 2013 - Novo Nordisk today announced the completion of paradigm(TM) 2, the first phase 3 trial with a long-acting FIX derivative, N9-GP (glycopegylated recombinant factor IX), for haemophilia B patients. Paradigm(TM) 2 is a multi-centre, blinded trial evaluating the safety and efficacy of N9-GP when used for on-demand or prophylactic treatment in patients with haemophilia B. Further information Media: Mike Rulis +45 3079 3573 [email protected] Ken Inchausti (US) +1 609 514 8316 [email protected] Investors: Kasper Roseeuw Poulsen +45 4442 4303 [email protected] Frank Daniel Mersebach +45 4442 0604 [email protected] Lars Borup Jacobsen +45 3075 3479 [email protected] Jannick Lindegaard (US) +1 609 786 4575 [email protected] Company announcement No 37 / 2013
The release as fetched from its publisher. novonordisk.com ↗